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normalized ratio (INR) monitoring in patients on vitamin K antagonists (VKA) on 
maintenance anticoagulation. Methods: This interim analysis is based on data of 
2863 patients enrolled in the PREFER in VTE registry in 7 Western European countries 
(France, Germany, Italy, Spain, UK, Austria and Switzerland). 1689 had DVT (only) 
and 1174 had PE (±DVT). Results: At 6-month follow-up, 51.5% of the patients were 
treated with VKA. INR measurements at 6-month follow-up (UK: 3 month) were 
performed in the hospital setting for 13.1% of these patients (most frequently in 
Spain 42.9%, UK 32.7%,, Italy 18.0%), in the anticoagulation center in 23.6% (in Spain 
40.0%, Italy 37.0%, UK 16.4%), in the physician’s office in 16.8% (Germany 90.7%, UK 
41.8%), by the patient self-measured in 4.9% (Spain 8.6%), or at biology labs or other 
institutions in 36.9% (France 92.4%). The patient’s mean travel distance to the INR 
site was 5.8 ±9.16 km overall, the range was 0-90 km (mean varied across countries 
from 2.4 to 7.7 km). Mean travel time was 14.3 ±18.4 min (across countries 5.7 to 
18.2 min). Patients most frequently used their private car/motorbike (50.8 %) or 
walked (16.4%). The mean number of INR measurements over the 6-month period 
was 16.8, the number of INR measurements per month was 2.8 ±1.2 overall (across 
countries 1.8 to 3.2). ConClusions: In the various countries, different institu-
tions are responsible for routine INR measurements. While biology labs are almost 
exclusively used in France, there is no equivalent for such institutions in other 
countries. INR self-measurement plays a minor role. Patients usually have the INR 
sites in their vicinity, and the average number of measurements shows little vari-
ation between countries.
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objeCtives: Atrial fibrillation (AF) is the most common cardiac arrhythmia, and 
accounts for one-third of hospitalizations for cardiac disturbances. The majority 
of descriptive data on management of AF patients are from western countries, 
with limited information available from the Middle East region. The objective of 
this study was to characterize treatment patterns and health resource utilization 
among AF patients in the Kingdom of Saudi Arabia (KSA) and United Arab Emirates 
(UAE). Methods: A retrospective chart review was undertaken at three hospitals 
in UAE and three in KSA, to identify AF patients diagnosed between January 2005 
and June 2010. Patient charts were sampled consecutively backwards by diagnosis 
date, from June 2010 until the target sample was reached. AF was identified based 
on ICD-9 code (427.31), from a sample of patients defined by any history of antico-
agulant use. Data on demographic and disease-related characteristics, treatment 
patterns, health resource utilization, and international normalized ratio (INR) con-
trol were abstracted from diagnosis until June 2012. Results: Among eligible AF 
patients (UAE, n= 157, KSA, n= 152), the majority were diagnosed with chronic AF 
(80.9% in UAE, 63.7% in KSA) as opposed to paroxysmal AF. Treatments prescribed to 
AF patients differed between countries: warfarin monotherapy was widely used in 
UAE (59.9%), while a variety of warfarin- and aspirin-based combination therapies 
were used in KSA, with no single dominant regimen. Warfarin + bisoprolol (12.5%) 
and aspirin + bisoprolol (10.5%) combination therapies were the most common 
regimens in KSA. Patterns of health care utilization also varied, with hospitalization 
and emergency room visits more common in KSA, and outpatient visits more com-
mon in UAE. ConClusions: Treatments and health resources used by AF patients 
varied between KSA and UAE. While some differences may result from differences 
in patient and disease characteristics, they likely also reflect variation in manage-
ment strategies across the regions.
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objeCtives: Individuals at high risk for cardiovascular events who fail to achieve 
treatment goal (LDL-C< 100 mg/dL) despite being on maximal lipid lowering treat-
ment qualify for apheresis, a procedure that costs approximately 40,000€ per patient 
per year in Germany. The current model aims to assess the ability of evolocumab 
(AMG 145), an investigational medication that is being evaluated in clinical trials, 
to reduce the proportion of patients requiring apheresis in Germany. Methods: 
Data on secondary prevention patients eligible for apheresis, excluding homozygous 
familial hypercholesterolemia patients, were extracted from the German IMS Disease 
Analyzer 2011-2013 database (n= 8,262) and included in the analysis. The calculated 
mean LDL-C reductions observed in the DESCARTES and LAPLACE-2 evolocumab tri-
als, ranging from 59.3% (95% CI [54.9%, 63.8%]) to 72.3% (95% CI [69.1%, 75.4%]), were 
applied to baseline LDL-C levels of the identified patient-profiles, following a proba-
bilistic approach. The goal for such patients was LDL-C< 100 mg/dL, as defined in the 
German lipid association (DGFF) guideline. Results: The mean ± standard deviation 
LDL-C levels of the sample decreased from 150.2 ± 32.9 mg/dL at baseline to 61.1 ± 
13.8 mg/dL (DESCARTES) and to 41.7 ± 9.5 mg/dL (LAPLACE-2) after evolocumab treat-
ment. From an initial proportion of 100% of patients eligible for apheresis at baseline, 
evolocumab treatment led to a proportion of 1% (DESCARTES) and 0% (LAPLACE-2) 
of patients requiring apheresis. Thus, in the analyzed population, apheresis-related 
costs could be largely reduced. ConClusions: The use of evolocumab in the treat-
ment algorithm of high-risk patients not at LDL-C goal could allow reducing the 
invasive, time-consuming, burdensome and costly weekly apheresis treatments. As a 
result, significant savings of apheresis-related costs could be achieved by the German 
Health Care System.
reduction. A predefined questionnaire was delivered to physicians’ and primary 
care payers’ (namely members of the regional health authorities) to survey their 
opinions about the value of this tool. Results: Overall opinion from 30 physicians 
and 11 primary care deciders (geographically distributed) was positive, averaging 
3.9 in a likert scale from 1 (strongly disagree) to 5 (strongly agree). Physicians aver-
aged 4 while primary care payers’ was 3.7. 71% of respondents ranked 4 to 5 in 
this overall assessment of the tool. Regarding more specific topics using the same 
likert scale, global, physicians’ and primary care deciders’ responses averaged as 
following, respectively: Utility of the tool: 3.6, 3.6 and 3.6; Relevance of the tool: 3.9, 
3.9 and 3.9; Value of the tool to understand LDL-C treatment targets: 4.0, 4.2 and 
3.6. ConClusions: This approach is useful to understand user’s opinions about a 
tool which aims primarily to raise awareness on the importance of the LDL-C reduc-
tion. Available evidence demonstrates that health care stakeholders in Portugal still 
need to understand the public health potential of LDL reduction. This tool might be 
of great value to address this need.
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objeCtives: Clinical guidelines recommend ACEIs (angiotensin converting enzyme 
inhibitors), ARBs (angiotensin receptor II blockers) for patients intolerant to ACEI, beta 
blockers (BBs), aldosterone antagonists (AAs) and diuretics as the pharmacological 
treatment for heart failure (HF). This study assesses the treatments prescribed within 
30 days post diagnosis among HF patients in a real world setting based on an admin-
istrative claims database in the US. Methods: This was a retrospective cohort study 
conducted using MarketScan database. Adult patients having ≥ 2 HF-related medical 
claims or 1 hospitalisation with primary HF diagnosis between April 2009 and March 
2012, and with a minimum of 12 months pre- and post-index continuous medical 
and pharmacy eligibility were included. Index date was defined as the first HF-related 
medical claim between April 2009 and March 2012. Patients with HF diagnosis in the 
12 months pre-index period were excluded. Demographics, clinical characteristics 
and index treatment (defined as a 30 days window period after HF diagnosis) were 
analysed. Results: Among 121,904 patients included in the analysis, 48.3% were > 75 
years of age and 35.0% were 18-64 years of age. Diabetes (27.0%), CV related condi-
tions (26%) and COPD (16.3%) were the most prevalent comorbidities. Overall, 37.6% 
patients were not prescribed any treatment related to HF within the first 30 days 
after HF diagnosis (no HF severity available). Among those prescribed treatment, the 
following treatment breakdown was observed: ACEIs, 29.3% of patients; ARBs, 8.5%; 
BBs, 46.6%; AAs, 7.4%; and diuretics, 45.7%. Prescription of fixed dose combination of 
ACEIs with diuretics or ARBs with diuretics was very limited. ConClusions: Findings 
suggest that a substantial proportion of patients do not receive HF specific medica-
tions following the month of diagnosis. Further research is necessary to explore the 
reasons for lower than expected HF medication claims in these patients considering 
their high risk for morbidity and mortality.
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objeCtives: Benzodiazepines (BZD) are often administered to patients with arterial 
hypertension in addition to antihypertensive agents. The aim of this study was to 
analyze patterns of BSD usage among hypertensive outpatients in Serbia according 
to sex and age. Methods: Data on BZD issued on prescription for the International 
classification of diseases (ICD) code I10 (essential arterial hypertension) were col-
lected from all state-owned pharmacies in Novi Sad (population 350,000) from 
September 2011 to February 2012. Consumption was calculated using the ATC/
DDD methodology. Results: BZD accounted for 2% of all drugs issued in treat-
ment of hypertension. The total amount of BZD issued was 2.27 DDD/1000inh/day. 
Bromazepam (51.38 %) and diazepam (37.56 %) were the most commonly used BSD 
and accounted for almost 90% of all BSD utilized. Lorazepam accounted for 8.36% 
of total consumption. Other agents (alprazolam, nitrazepam, midazolam, klonaz-
epam) accounted for less than 3% altogether. The BZD consumption increased with 
patient’s age – 91% being prescribed to the patients over the age of 50. Consumption 
was highest in age group 70-80 years. BZD were more often prescribed to female 
(68.63%) than to male outpatients (31.37%). ConClusions: This study confirmed 
consumption of BZD among outpatients with hypertension. It is most common 
in hypertensive female and elderly population. However, since the benefits of 
BZD administration in hypertension control remain unclear, the adequacy of this 
practice is questionable. This work was supported by the Ministry of Science and 
Technological Development, Republic of Serbia, project No. 41012.
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objeCtives: In patients with acute deep venous thrombosis (DVT) or pulmonary 
embolism (PE) there is a lack of comparative data on the logistics of international 
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anxiety disorders in 65%, ADHD in 61%, impaired social behaviour in 85%, depres-
sion in 23%, and seizures in 4%. Medical therapy for comorbidities was often 
prescribed. ConClusions: The registry is expected to provide much-needed data 
on the characteristics and management situation of FXS patients in Germany, to 
allow comparisons with other countries, and to enable gap analyses based on 
current guidelines for management of these patients. ClinTrials. gov identifier 
is NCT01711606.
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objeCtives: To conduct a systematic review of randomised controlled trials 
comparing effectiveness of GnRHa in the treatment of endometriosis in order to 
assess the feasibility of conducting a meta-analysis and indirect treatment com-
parison. Methods: Inclusion criteria were all published randomized controlled 
trials comparing GnRHa versus any other pharmacological treatment or placebo 
in the treatment of laparoscopically confirmed moderate to severe endometriosis. 
Electronic databases were searched up to February 2014 (Embase, Medline, Cochrane, 
Clintrials. gov and clinical conferences). Search results were screened, eligible stud-
ies were assessed for risk of bias and data extracted. Studies were evaluated for 
the feasibility of inclusion into a network meta-analysis. Results: A total of 1,670 
titles and abstracts were screened. Sixty-nine papers relating to 62 studies were 
identified as eligible for inclusion. Fourteen of the 62 were excluded due to high 
risk of bias, a further 21 did not present sufficient data. The remaining 27 studies 
showed clinical heterogeneity in the measurement of disease severity and efficacy 
outcomes and quality of reporting. Efficacy outcomes were measured using various 
methods and at different time points (3, 6 to 12 months). All but one measured pain, 
12 using modified versions of the Biberoglu and Behrman (B&B), 7 using a similar 
method and 4 used a visual analogue scale. Quality of life was measured in 7 studies, 
most commonly by a generic HRQoL instrument, the SF-36. Adverse event recording 
varied. ConClusions: A core set of studies were identified that could be incorpo-
rated into a quantitative analysis assessing effectiveness of GnRHa for treatment of 
moderate to severe endometriosis over 6 months. A network meta-analysis would 
potentially be feasible using more commonly reported pain outcomes, (modified) 
B&B; HRQoL and reported adverse events.
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objeCtives: The present study iims to meta-analyze clinical trials evaluating the 
efficacy of oximes on organophosphorus (OP) poisoning treatment. Methods: 
PubMed, Scopus, Google Scholar, and clinicaltials. gov were searched for studies 
investigating the effects of oximes in the treatment of OP poisoning. Mortality, 
intermediate syndrome, intensive care unit (ICU) admission rate, hospital stay dura-
tion, and intubation rate were the key outcomes of interest. Data were searched in 
the time period of 1966 through December 2013. Results: Thirteen studies (eleven 
clinical trials and two historical cohorts) that met our criteria were included in 
the analysis. Pooling of data showed that relative risk (RR) of need for intubation 
in OP poisoning for eight included trials comparing oximes with placebo was 1.27 
with 95% CI= 0.73 to 2.23 (P= 0.4). RR of only one observational study was 1.57 (95% 
CI= 0.79 to 3.2, P> 0.05). The summary of RR for mortality rate in 9 studies was 0.38 
(95% CI= 0.65 to 2.97, P= 0.41) and for one observational study was 1.33 (95% CI= 
0.54 to 3.29, P> 0.05). The RR for ICU admission rate in OP poisoning for three trials 
comparing oximes to placebo was2.12 with 95% CI= 0.89 to 5.03 (P= 0.09). For only 
one observational study, RR was 0.81 (95% CI= 0.49 to 1.25, P> 0.05). For intermediate 
syndrome, while the RR of only trial comparing oximes with placebo was 1.89 (95% 
CI= 1.27 to 2.91, P< 0.05), for only one observational study, it was 1.43 (95% CI= 0.7 
to 2.96, P> 0.05). For hospital stay duration, the RR of four studies was 0.75 with 95% 
CI = -0.51 to 1.99. ConClusions: According to these data, oximes beneficence in 
OP poisoning is unclear and there is possible increase in incidence of intermediate 
syndrome.
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objeCtives: The number of women whose labours are induced is increasing with 
average rates in England in excess of 20%. A broad range of methods for induction 
are available, including pharmacological, mechanical and alternative interventions 
with considerable variation in effectiveness, safety and cost. Of the pharmaco-
logical interventions, the most commonly used are prostaglandins. However, even 
within this class, there are a variety of different prostaglandins with a variety of 
modes of administration. The aim of this piece of work is to identify the most cost-
effective and safe prostaglandin for cervical ripening and labour induction in the 
NHS setting. Methods: A systematic review and network meta-analysis (NMA) of 
all relevant randomised trials comparing all prostaglandins for labour induction, 
and a cost-effectiveness analysis represented in the form of a decision tree model 
incorporating cost and maternal and neonatal health outcomes. Results: The NMA 
of randomised controlled trials comparing 11 different types of prostaglandins for 
labour induction demonstrated that the best treatment for achieving a vaginal birth 
within 24 hours was vaginal misoprostol tablet ≥ 50μ g with a probability of being 
indiVidual’s HealTH – Clinical outcomes studies
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objeCtives: Adverse drug event (ADEs), hospitalizations, and emergency department 
(ED) visits are important sequelae of inappropriate prescribing. Explicit measures are 
useful methods to detect inappropriate prescribing in the elderly. This study com-
pares the predictive validity of the 2002 Beers, 2012 Beers, and the STOPP criteria 
for these outcomes. Methods: A retrospective cohort design was implemented 
using commercial claims data between 2006 and 2009. Subjects included those 65 
years and older continuously eligible for medical and pharmacy benefits for at least 
6 months to assess baseline comorbidities and 3 months of follow-up. Time vary-
ing cox proportional hazard models were estimated using a monthly time interval 
where indicators of inappropriate prescribing exposure in month (i-1) where related 
to outcomes in month (i) to minimize temporal ambiguity between exposure and 
outcome. Measures of model discrimination (c-index) and hazard ratios (HR) were 
calculated to compare un-adjusted and adjusted models with the 2002 Beers, 2012 
Beers, and STOPP exposures models. Results: The final cohort included 174,275 
contributing 361,621 person years of follow up. The prevalence of inappropriate pre-
scribing was 34.1%, 32.2%, and 27.6% for the 2012 Beers, 2002 Beers, and the STOPP 
criteria and the rates of ADEs, ED, and hospital visits were 21.0, 140.3, 67.2 per 1000 
person years. All inappropriate prescribing criteria modestly discriminated ADEs 
in unadjusted analyses: STOPP (HR= 2.89 [2.68-3.12]; C-index= 60.7%), 2012 Beers 
(HR= 2.51 [2.33-2.70]; C-index= 60.3%), 2002 Beers (HR= 2.65 [2.46-2.85]; C-index= 60.5%). 
Similar results for model discrimination measures were observed for ED visits (STOPP 
[C-index= 59.0%], 2012 Beers [C-index= 58.5%], 2002 Beers [C-index= 58.5%]) and 
hospitalizations (STOPP [C-index= 59.8%], 2012 Beers [C-index= 59.0%], 2002 Beers 
[C-index= 58.8%]). ConClusions: All three of the criteria were modestly prognostic 
for ADEs, EDs, and hospitalizations with the STOPP criteria slightly outperforming the 
Beers criteria. Inappropriate prescribing is common in the elderly and significantly 
increases the risk of subsequent hospitalizations, ED visits, and ADEs.
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objeCtives: In Germany, the share of persons aged > 65 years is 21%. Germany there-
fore has the highest share of older inhabitants compared to other european coun-
tries. The aim of the present study was to evaluate the prevalence of defined chronic 
diseases among older patients (> 65 years) in German general practitioner (GP) prac-
tices. Methods: Data from Disease Analyzer database including 1,100 GPs were used. 
2,722,706 patients with at least one consultation in the time between April 2013 and 
March 2014 were included and analyzed. Results: Overall, 774,361 (28.4%) of patients 
by GPs were over 65 years. In patients aged > 65 years 66% were diagnosed with hyper-
tension, 41% with lipid metabolism, 33% with diabetes mellitus, 29% with coronary 
heart disease, 20% with rheumatoid arthritis, 19% with cancer, 15% with chronic 
obstructive pulmonary disease and 14% with heart insufficiency. ConClusions: 
Patients older than 65 years make up 28% and therefore comprise the main client 
group of GPs. The prevalence of chronic diseases is in this age very high. On account 
of their multimorbidity, the care of these patients is challenging. It is therefore impor-
tant to place particular emphasis on geriatric patient care as a part of the study of 
medicine as well as in physicians assistant degree programs.
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objeCtives: The Fragile X syndrome (FXS), caused by a CGG repeat expansion 
in the FMR1 gene on the X chromosome, is the most common inherited form of 
mental retardation and autism. Representative data on the characteristics and 
management of FXS patients in Germany are lacking. Methods: EXPLAIN FXS 
is an ongoing prospective longitudinal observational study which evaluates char-
acteristics and management of patients with a genetically confirmed diagnosis of 
FXS in ambulatory care. The registry uses a non-probability sampling approach to 
collect data on the characteristics, therapeutic drug and non-drug interventions, 
psychosocial parameters, quality of life, caregiver burden, and health economic 
parameters such as hospitalisation days. Results: After an average 9-month 
recruitment period in 10 centres, 33 patients have been included (86% males, 
mean age 22 years, age range 2- 82 years). Only 1 and 4 patient attended regular 
school, or regular school with integration measures, whereas the others were in 
special schools for the mentally impaired. Siblings were affected by FXS in 59% 
(10% unknown). On the 6-item FXS disease score by Giangreco (on 25 patients), 
the mean value was 6.7 ±2.4 points (range 2.4 to 11.0). Autistic behaviour was 
noted in 89%, hyperactivity in 50%, impaired intelligence in 96%. An FXS phe-
notype was often met, as 63% of patients were described to have a long, narrow 
face, and 89% large or prominent ears. Comorbidities were frequent, in particular 
